Durable Response to Durvalumab in Occult Small‐Cell Lung Cancer With Immune Checkpoint Inhibitor–Related Inflammatory Arthritis With Polymyalgia Rheumatica–Like Features

Geriatrics and gerontology international/Geriatrics & gerontology international 2026 Open access

Read full text
Authors: Akihito Fujimi, Naofumi Yamauchi, Ken Sato, Yasuhiro Nagamachi, Takuji Nishisato, Kohichi Takada
DOI: 10.1111/ggi.70678
Cited by: 1
References: 6

Abstract

We report a case of occult small-cell lung cancer with durable disease control during durvalumab therapy for 51 months. The patient developed immune checkpoint inhibitor-related inflammatory arthritis with polymyalgia rheumatica-like features, highlighting diagnostic challenges and the importance of functional independence in older adults.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Vasculitis and related conditions Peripheral Neuropathies and Disorders

Publication details

Journal / source
Geriatrics and gerontology international/Geriatrics & gerontology international
Publisher
Wiley
Volume
26
Issue
7
Pages
e70678–e70678
Publication date
1 July 2026
Language
EN